October 18, 2023 06:54 AM EDT

Takeda's stem cell therapy flunks PhIII test studying the drug in Crohn's disease

Takeda’s allogeneic stem cell therapy flunked a Phase III study for the treatment of a common complication of Crohn’s disease,

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Takeda's stem cell ther­a­py flunks PhI­II test study­ing the drug in Crohn's dis­ease